To learn more on the 2022 Consensus statement on the current pharmacological prevention and management of heart failure, access the full article
aPooled patient-level analysis of ORION-9, -10 and -11 phase 3 trials of LEQVIO vs placebo in 3,660 adult patients with HeFH, ASCVD or ASCVD risk equivalents (T2DM, FH and 10-year risk of a CV event >20% as assessed by Framingham risk score) and elevated LDL-C, on a background of maximally tolerated statin (unless intolerant or contraindicated) ± ezetimibe. Co-primary endpoints: placebo-corrected reduction from baseline in LDL-C at Day 510 (17 months) of 50.7% (95% CI -52.9, -48.4; p<0.0001); placebo-corrected time-adjusted reduction in LDL-C from baseline between Day 90
(3 months) and Day 540 (18 months) of 50.5% (95% CI -52.1, -48.9; p<0.0001).2
References: 1. Australian Institute of Health and Welfare. 2024. Heart, stroke and vascular disease: Australian facts. Available at www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvdfacts/ contents/about (accessed August 2024).
ENTRESTO PBS Information: Authority required (STREAMLINED) for chronic heart failure. Patients must be NYHA Class II–IV, have LVEF ≤40% and be receiving optimal standard chronic heart failure treatment. Refer to PBS Schedule for full Authority Information
For ENTRESTO Product Information, please click here.
LEQVIO PBS Information: Authority Required (STREAMLINED) for patients with hypercholesterolaemia.
Refer to PBS Schedule for full Authority information.
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reportingproblems.
For LEQVIO (inclisiran) prescribing information, please click here.
This content is intended for Australian healthcare professionals and is promotional.
ENTRESTO® and the ENTRESTO® logo are registered trademarks of Novartis AG. LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG.
Please note, by leaving this page, you may access promotional content on this website. Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. ® Registered Trademark Item No:
AU-27066, Date of Preparation September 2024
Meet the presenters
The sessions and content covered were independently chosen by the speakers. The content discussed is the thoughts of the speakers and not necessarily that of Novartis.
RACP CPD Forms
You may be able to claim CPD points for the hours spent on this educational activity. See below for the relevant forms.
To support you in documenting CPD points per the RACP college requirements, please find below a link to the Certificate of Completion to capture what videos you have watched.
According to the RACP, you may consider claiming CPD points for this activity under Category 1 as per the 2021 RACP MyCPD Framework.
This contributes to 1 credit per every hour spent on watching the videos. You will be able to upload the completed Reflection Form to your RACP MyCPD account as proof of completion.
To support you in documenting CPD points per the RACP college requirements, please find below a link to the Reflection Form. You will be able to use this form to reflect on what knowledge you already have in this area prior to watching the videos, followed by what you have learnt after watching the videos and how it may change your practice.
According to the RACP, you may consider claiming CPD points for this reflection activity under Category 2 as per the 2021 RACP MyCPD Framework.
This contributes to 3 credits per every hour spent on the Reflection Form. You will be able to upload the completed Reflection Form to your RACP MyCPD account as proof of completion.
EULAR 2022 Novartis Posters
Novartis poster presentations will be available following the close of EULAR. Please check back later.
EULAR 2022 Novartis Sponsored Symposium
The Novartis Sponsored Symposium will be available following the close of EULAR. Please check back later.
This presentation may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities and where efficacy and safety have not been established. In such cases, there is no guarantee that they will receive regulatory approval and become commercially available. The presentation content is provided exclusively for medical education purposes.
Novartis recommends the use of its products according to their Product Information approved by the Therapeutic Goods Administration. Please check the approved Product Information before prescribing. Product Information is available upon request, or at: https://www.novartis.com.au/products/healthcare-professionals
Please note, by leaving this page, you may access promotional content on this website.
Sign up now for MedHub to access more medical education content from Novartis delivered to your email.
Your request has been received and in review with MedHub. No further action is required now.
All the fields are mandatory. Please fill in the required fields and try again.
Medical Information Service
Medical Enquiries, Information services, Adverse Events and Product Complaints please contact:
Colleagues are available from 9:00 to 17:00 AEST from Monday to Friday
Medical Education
Request Samples
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies.
Close ×
Title
Subtitle
Description
Close ×
Contact our Medical Team
You can request a call back by filling in this form.
I confirm that I am a current practicing Health Care Practitioner in Australia. *
Your request has been saved successfully. A member of our medical team will be in touch with you shortly. You can close this pop-up to review the main event details.
All fields marked with * are mandatory. Please fill in the required fields and try again.
Close ×
Opt out of INCLISIRAN LDLC VIDEO Emails
You can request to opt out of INCLISIRAN LDLC VIDEO Emails by filling in this form.
Your request has been saved successfully.
All fields marked with * are mandatory. Please fill in the required fields and try again.
Close ×
A brief guide to the 2022 heart failure consensus statement
This guide to the 2022 Australian heart failure consensus statement provides an easy to understand summary of the latest guidance on the treatment of HFrEF
